FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214878546> ?p ?o ?g. }

• W3214878546 endingPage "4765" @default.
• W3214878546 startingPage "4765" @default.
• W3214878546 abstract "Abstract Background Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the induction treatment of multiple myeloma (MM) transplant eligible and ineligible patients. Deregulation of histone acetylation has been recognized to serve a critical role in the pathogenesis of MM, which histone deacetylase (HDACs) are overexpressed in plasma cells derived from patients with MM. Therefore, HDACs may promise targets for MM therapy, and panobinostat was approved by FDA for the treatment of relapsed/refractory MM in 2015. Chidamide, a novel oral benzamide type HDAC inhibitor independently developed and approved as anticancer drugs in China, selectively suppresses the activity of class I HDACs. Our studies have shown that chidamide can enhance cytotoxic effect of bortezomib or lenalidomide on MM cells in vitro, which suggested a synergistic combination of chidamide with bortezomib or lenalidomide at low dose. In ASH 2019 we reported Phase 1 Suzhou MM02 study in which chidamide at 4 dose levels (15mg/20mg/25mg/30mg d 0,3,7,10) were administered to 12 patients with VRd for 4-cycle induction therapy. No DLT in Chi-VRd group were observed. This phase 2 trial was designed to further assess the safety and efficacy of Chi-VRd versus VRd for induction treatment in patients with newly diagnosed high risk MM before autologous transplantation (NCT 04025450). Methods In this study, we enrolled patients from the First Affiliated Hospital of Soochow University and Soochow Hopes Hematology Hospital with newly diagnosed high-risk multiple myeloma who were aged 18 years or older and eligible for autologous stem-cell transplant (ASCT) according to International Myeloma Working Group diagnostic criteria. All the patients were randomly assigned to Chi-VRd and VRd group. Chi-VRd group patients received Chidamide 20mg orally on days -1,2,6 and 9 in combination with VRd (bortezomib 1.3mg/m2 subcutaneously on days 1,4,8,11; lenalidomide 25mg orally on days 1-14; dexamethasone 20mg iv or orally on days 1,2,4,5,8,9,11,12) for 4 cycles. VRd group patients received VRd (bortezomib 1.3mg/m2 subcutaneously on days 1,4,8,11; lenalidomide 25mg orally on days 1-14; dexamethasone 20mg iv or orally on days 1,2,4,5,8,9,11,12) for 4 cycles. All the patients proceed with ASCT after four cycles or continue VRd therapy for up to eight cycles, followed by maintenance therapy for up to 2 years. Primary efficacy endpoints were overall response rate (ORR), rate of very good partial response (VGPR) or better and rate of complete response (CR) for Chi-VRd and VRd. Safety data described rates of adverse events. Results Between Mar 16, 2020, and Jul 22, 2021, 40 patients were enrolled and randomly assigned to either the VRd regimen (n=20) or the Chi-VRd regimen (n=20). In the Chi-VRd group, 1 patient was discharged due to severe tumor lysis syndrome, and another 1 patient was discharged from sick sinus syndrome (considering lenalidomide related). By the deadline for submission, 18 patients in the VRd group and 11 patients in the Chi-VRd group had completed induction chemotherapy. The total adverse events were listed in the table below. The main treatment-related adverse events were hematological toxicity, hepatotoxicity, constipation, and peripheral neuropathy. ORR was 90.9% (10/11) for Chi-VRd and was 100% for VRd. Response of VGPR or better was 81.8% (9/11) for Chi-VRd and was 83.3% (15/18) for VRd. And rate of CR was 63.6%(7/11) for Chi-VRd and was 44.4%(8/18) for VRd. Conclusion The Chi-VRd group had more adverse events of thrombocytopenia, peripheral neuropathy and pulmonary. No treatment-related death was observed in two groups. Patients received Chi-VRd get more CR rate. Updated PFS and OS with comparison between VRd and Chi-VRd will be presented at the following study. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3214878546 created "2021-12-06" @default.
• W3214878546 creator A5006739024 @default.
• W3214878546 creator A5025565899 @default.
• W3214878546 creator A5035357574 @default.
• W3214878546 creator A5051994266 @default.
• W3214878546 creator A5056803951 @default.
• W3214878546 creator A5074990119 @default.
• W3214878546 creator A5082647291 @default.
• W3214878546 creator A5090884672 @default.
• W3214878546 date "2021-11-05" @default.
• W3214878546 modified "2023-10-18" @default.
• W3214878546 title "Phase 2 Suzhou MM02 Study: Chidamide with VRD Versus VRD in Newly Diagnosed High Risk Transplant Eligible Multiple Myeloma Patients" @default.
• W3214878546 doi "https://doi.org/10.1182/blood-2021-152390" @default.
• W3214878546 hasPublicationYear "2021" @default.
• W3214878546 type Work @default.
• W3214878546 sameAs 3214878546 @default.
• W3214878546 citedByCount "1" @default.
• W3214878546 countsByYear W32148785462023 @default.
• W3214878546 crossrefType "journal-article" @default.
• W3214878546 hasAuthorship W3214878546A5006739024 @default.
• W3214878546 hasAuthorship W3214878546A5025565899 @default.
• W3214878546 hasAuthorship W3214878546A5035357574 @default.
• W3214878546 hasAuthorship W3214878546A5051994266 @default.
• W3214878546 hasAuthorship W3214878546A5056803951 @default.
• W3214878546 hasAuthorship W3214878546A5074990119 @default.
• W3214878546 hasAuthorship W3214878546A5082647291 @default.
• W3214878546 hasAuthorship W3214878546A5090884672 @default.
• W3214878546 hasBestOaLocation W32148785461 @default.
• W3214878546 hasConcept C104317684 @default.
• W3214878546 hasConcept C126322002 @default.
• W3214878546 hasConcept C141071460 @default.
• W3214878546 hasConcept C143998085 @default.
• W3214878546 hasConcept C2776063141 @default.
• W3214878546 hasConcept C2776364478 @default.
• W3214878546 hasConcept C2777478702 @default.
• W3214878546 hasConcept C2778305200 @default.
• W3214878546 hasConcept C2780225316 @default.
• W3214878546 hasConcept C2781413609 @default.
• W3214878546 hasConcept C2911091166 @default.
• W3214878546 hasConcept C55493867 @default.
• W3214878546 hasConcept C64927066 @default.
• W3214878546 hasConcept C71924100 @default.
• W3214878546 hasConcept C86803240 @default.
• W3214878546 hasConcept C90924648 @default.
• W3214878546 hasConceptScore W3214878546C104317684 @default.
• W3214878546 hasConceptScore W3214878546C126322002 @default.
• W3214878546 hasConceptScore W3214878546C141071460 @default.
• W3214878546 hasConceptScore W3214878546C143998085 @default.
• W3214878546 hasConceptScore W3214878546C2776063141 @default.
• W3214878546 hasConceptScore W3214878546C2776364478 @default.
• W3214878546 hasConceptScore W3214878546C2777478702 @default.
• W3214878546 hasConceptScore W3214878546C2778305200 @default.
• W3214878546 hasConceptScore W3214878546C2780225316 @default.
• W3214878546 hasConceptScore W3214878546C2781413609 @default.
• W3214878546 hasConceptScore W3214878546C2911091166 @default.
• W3214878546 hasConceptScore W3214878546C55493867 @default.
• W3214878546 hasConceptScore W3214878546C64927066 @default.
• W3214878546 hasConceptScore W3214878546C71924100 @default.
• W3214878546 hasConceptScore W3214878546C86803240 @default.
• W3214878546 hasConceptScore W3214878546C90924648 @default.
• W3214878546 hasIssue "Supplement 1" @default.
• W3214878546 hasLocation W32148785461 @default.
• W3214878546 hasOpenAccess W3214878546 @default.
• W3214878546 hasPrimaryLocation W32148785461 @default.
• W3214878546 hasRelatedWork W1967461244 @default.
• W3214878546 hasRelatedWork W2031089824 @default.
• W3214878546 hasRelatedWork W2048722552 @default.
• W3214878546 hasRelatedWork W2162611585 @default.
• W3214878546 hasRelatedWork W2738602720 @default.
• W3214878546 hasRelatedWork W2751497063 @default.
• W3214878546 hasRelatedWork W2980910443 @default.
• W3214878546 hasRelatedWork W2981018427 @default.
• W3214878546 hasRelatedWork W3127479238 @default.
• W3214878546 hasRelatedWork W3134875278 @default.
• W3214878546 hasVolume "138" @default.
• W3214878546 isParatext "false" @default.
• W3214878546 isRetracted "false" @default.
• W3214878546 magId "3214878546" @default.
• W3214878546 workType "article" @default.